JPMorgan Chase & Co. Has $476.41 Million Stake in Kenvue Inc. (NYSE:KVUE)

JPMorgan Chase & Co. lessened its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 24.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,314,306 shares of the company's stock after selling 7,138,646 shares during the quarter. JPMorgan Chase & Co. owned 1.16% of Kenvue worth $476,410,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Grove Bank & Trust grew its position in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the 4th quarter valued at $29,000. SRS Capital Advisors Inc. boosted its holdings in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC increased its position in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after buying an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of KVUE stock traded down $0.14 during mid-day trading on Tuesday, reaching $23.85. The stock had a trading volume of 11,113,788 shares, compared to its average volume of 16,722,053. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The firm has a market cap of $45.57 billion, a PE ratio of 44.99, a P/E/G ratio of 2.62 and a beta of 1.25. The firm's 50 day simple moving average is $22.38 and its 200 day simple moving average is $22.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.44%. Kenvue's payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KVUE. Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. UBS Group dropped their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Barclays upped their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a report on Thursday, March 27th. Evercore ISI began coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. Finally, Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.